Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.25
CRL's Cash to Debt is ranked lower than
52% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. CRL: 0.25 )
CRL' s 10-Year Cash to Debt Range
Min: 0.04   Max: 15.68
Current: 0.25

0.04
15.68
Equity to Asset 0.39
CRL's Equity to Asset is ranked higher than
52% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. CRL: 0.39 )
CRL' s 10-Year Equity to Asset Range
Min: -0.3   Max: 0.72
Current: 0.39

-0.3
0.72
Interest Coverage 7.22
CRL's Interest Coverage is ranked higher than
51% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 138.50 vs. CRL: 7.22 )
CRL' s 10-Year Interest Coverage Range
Min: 1.6   Max: 83.91
Current: 7.22

1.6
83.91
F-Score: 7
Z-Score: 2.55
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 12.99
CRL's Operating margin (%) is ranked higher than
87% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. CRL: 12.99 )
CRL' s 10-Year Operating margin (%) Range
Min: -33.48   Max: 22.58
Current: 12.99

-33.48
22.58
Net-margin (%) 8.82
CRL's Net-margin (%) is ranked higher than
86% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. CRL: 8.82 )
CRL' s 10-Year Net-margin (%) Range
Min: -38.84   Max: 14.3
Current: 8.82

-38.84
14.3
ROE (%) 16.04
CRL's ROE (%) is ranked higher than
89% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. CRL: 16.04 )
CRL' s 10-Year ROE (%) Range
Min: -48.98   Max: 20.85
Current: 16.04

-48.98
20.85
ROA (%) 6.25
CRL's ROA (%) is ranked higher than
81% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. CRL: 6.25 )
CRL' s 10-Year ROA (%) Range
Min: -24.16   Max: 10.02
Current: 6.25

-24.16
10.02
ROC (Joel Greenblatt) (%) 18.11
CRL's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. CRL: 18.11 )
CRL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -47.95   Max: 53.14
Current: 18.11

-47.95
53.14
Revenue Growth (%) 9.90
CRL's Revenue Growth (%) is ranked higher than
80% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. CRL: 9.90 )
CRL' s 10-Year Revenue Growth (%) Range
Min: -17.6   Max: 13.4
Current: 9.9

-17.6
13.4
» CRL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CRL Guru Trades in Q1 2013

RS Investment Management 17,700 sh (New)
Jim Simons 1,443,409 sh (+121.69%)
Paul Tudor Jones 10,200 sh (+67.21%)
PRIMECAP Management 901,800 sh (+66.63%)
Robert Olstein 172,000 sh (+39.84%)
John Rogers 2,763,450 sh (+0.71%)
Westport Asset Management 155,000 sh (unchged)
Joel Greenblatt Sold Out
David Dreman 870,399 sh (-12.74%)
Steven Cohen 13,890 sh (-44.88%)
» More
Q2 2013

CRL Guru Trades in Q2 2013

Pioneer Investments 45,900 sh (New)
Joel Greenblatt 50,187 sh (New)
RS Investment Management 704,725 sh (+3881.5%)
PRIMECAP Management 1,639,900 sh (+81.85%)
Robert Olstein 176,000 sh (+2.33%)
Westport Asset Management 155,000 sh (unchged)
Steven Cohen 125,000 sh (unchged)
John Rogers 2,734,450 sh (-1.05%)
Paul Tudor Jones 9,600 sh (-5.88%)
David Dreman 746,022 sh (-14.29%)
Jim Simons 1,184,309 sh (-17.95%)
Steven Cohen 8,573 sh (-38.28%)
» More
Q3 2013

CRL Guru Trades in Q3 2013

Ken Fisher 52,400 sh (New)
Steven Cohen 23,076 sh (+169.17%)
Pioneer Investments 101,212 sh (+120.51%)
PRIMECAP Management 1,697,800 sh (+3.53%)
John Rogers 2,749,905 sh (+0.57%)
Westport Asset Management 155,000 sh (unchged)
Robert Olstein 176,000 sh (unchged)
RS Investment Management 696,761 sh (-1.13%)
Paul Tudor Jones 8,700 sh (-9.38%)
Joel Greenblatt 41,454 sh (-17.4%)
Jim Simons 906,209 sh (-23.48%)
David Dreman 187,877 sh (-74.82%)
» More
Q4 2013

CRL Guru Trades in Q4 2013

Steven Cohen 38,698 sh (+67.7%)
Pioneer Investments 131,209 sh (+29.64%)
David Dreman 212,072 sh (+12.88%)
Paul Tudor Jones 9,300 sh (+6.9%)
Ken Fisher 54,280 sh (+3.59%)
Westport Asset Management 155,000 sh (unchged)
PRIMECAP Management 1,697,800 sh (unchged)
RS Investment Management 689,250 sh (-1.08%)
Robert Olstein 169,000 sh (-3.98%)
John Rogers 2,629,217 sh (-4.39%)
Jim Simons 666,709 sh (-26.43%)
Joel Greenblatt 21,759 sh (-47.51%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-12-31 Reduce -47.51%0.03%$44.67 - $53.36 $ 56.813%21759
David Dreman 2013-09-30 Reduce -74.82%0.74%$41.84 - $48.15 $ 56.824%187877
David Dreman 2013-06-30 Reduce -14.29%0.14%$40.86 - $45.51 $ 56.833%746022
Joel Greenblatt 2013-06-30 New Buy0.09%$40.86 - $45.51 $ 56.833%50187
PRIMECAP Management 2013-06-30 Add 81.85%0.04%$40.86 - $45.51 $ 56.833%1639900
Joel Greenblatt 2013-03-31 Sold Out 0.02%$37.47 - $45.79 $ 56.836%0
PRIMECAP Management 2013-03-31 Add 66.63%0.02%$37.47 - $45.79 $ 56.836%901800
Joel Greenblatt 2012-12-31 Reduce -68.06%0.06%$35.65 - $41.24 $ 56.846%9794
Joel Greenblatt 2012-09-30 Reduce -27.18%0.03%$32.27 - $39.6 $ 56.859%30668
Joel Greenblatt 2012-06-30 Add 25.2%0.02%$31.91 - $36.62 $ 56.867%42112
Joel Greenblatt 2012-03-31 Reduce -49.74%0.11%$27.39 - $37.02 $ 56.879%33635
PRIMECAP Management 2012-03-31 Add 125.26%0.01%$27.39 - $37.02 $ 56.879%470112
Ray Dalio 2012-03-31 Sold Out 0.0038%$27.39 - $37.02 $ 56.879%0
Arnold Van Den Berg 2011-12-31 Sold Out 0.09%$25.95 - $33.57 $ 56.898%0
Joel Greenblatt 2011-12-31 Add 69.76%0.09%$25.95 - $33.57 $ 56.898%66917
PRIMECAP Management 2011-12-31 Add 177.9%0.01%$25.95 - $33.57 $ 56.898%208700
Ray Dalio 2011-12-31 Reduce -29.15%$25.95 - $33.57 $ 56.898%8289
Joel Greenblatt 2011-09-30 Add 111.92%0.1%$28.5 - $42.05 $ 56.863%39419
Ray Dalio 2011-09-30 New Buy0.01%$28.5 - $42.05 $ 56.864%11700
George Soros 2011-09-30 Sold Out 0.0038%$28.5 - $42.05 $ 56.863%0
Jean-Marie Eveillard 2011-09-30 Sold Out 0.0018%$28.5 - $42.05 $ 56.863%0
Joel Greenblatt 2011-06-30 Reduce -20.11%0.05%$37.38 - $42.3 $ 56.842%18601
Joel Greenblatt 2011-03-31 New Buy0.27%$35.54 - $39.39 $ 56.851%23284
George Soros 2011-03-31 Reduce -71.49%$35.54 - $39.39 $ 56.851%6700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 26.60
CRL's P/E(ttm) is ranked higher than
55% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. CRL: 26.60 )
CRL' s 10-Year P/E(ttm) Range
Min: 8.59   Max: 95.93
Current: 26.6

8.59
95.93
P/B 4.30
CRL's P/B is ranked lower than
53% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. CRL: 4.30 )
CRL' s 10-Year P/B Range
Min: 0.75   Max: 5.58
Current: 4.3

0.75
5.58
P/S 2.36
CRL's P/S is ranked higher than
65% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. CRL: 2.36 )
CRL' s 10-Year P/S Range
Min: 1.12   Max: 3.91
Current: 2.36

1.12
3.91
PFCF 16.30
CRL's PFCF is ranked higher than
70% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. CRL: 16.30 )
CRL' s 10-Year PFCF Range
Min: 8.48   Max: 907.57
Current: 16.3

8.48
907.57
EV-to-EBIT 21.30
CRL's EV-to-EBIT is ranked higher than
52% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. CRL: 21.30 )
CRL' s 10-Year EV-to-EBIT Range
Min: 7.3   Max: 72.3
Current: 21.3

7.3
72.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.40
CRL's Price/Tangible Book is ranked lower than
69% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. CRL: 8.40 )
CRL' s 10-Year Price/Tangible Book Range
Min: 2.93   Max: 12.62
Current: 8.4

2.93
12.62
Price/DCF (Projected) 1.40
CRL's Price/DCF (Projected) is ranked higher than
75% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. CRL: 1.40 )
CRL' s 10-Year Price/DCF (Projected) Range
Min: 0.94   Max: 1.78
Current: 1.4

0.94
1.78
Price/Median PS Value 1.00
CRL's Price/Median PS Value is ranked higher than
79% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. CRL: 1.00 )
CRL' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.5
Current: 1

0.5
1.5
Price/Graham Number 3.10
CRL's Price/Graham Number is ranked lower than
63% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. CRL: 3.10 )
CRL' s 10-Year Price/Graham Number Range
Min: 1.66   Max: 5.55
Current: 3.1

1.66
5.55
Earnings Yield (Greenblatt) 4.70
CRL's Earnings Yield (Greenblatt) is ranked higher than
57% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. CRL: 4.70 )
CRL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 13.7
Current: 4.7

1.4
13.7
Forward Rate of Return (Yacktman) 3.68
CRL's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. CRL: 3.68 )
CRL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 21.4
Current: 3.68

2.9
21.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RV6.Germany
Charles River Laboratories International Inc, a Delaware corporation was incorporated in 1994. In 2000, it completed its initial public offering. The Company is a global provider of solutions that accelerate the drug discovery and development process, including research models and associated services, and outsourced preclinical services. It currently has two reporting segments: Research Models and Services (RMS) and Preclinical Services (PCS). The Company has been supplying research models to the drug development industry since 1947. The RMS segment is comprised of Research Models, Research Model Services and Endotoxin and Microbial Detection (EMD). It provides its rodent models to numerous customers, including most pharmaceutical companies, a range of biotechnology companies, many government agencies, and hospitals and academic institutions. Research Model Services capitalize on the technologies and relationships developed through its research model business, and address the need among pharmaceutical and biotechnology companies to outsource the non-core aspects of their drug discovery activities. These services include those which are related to maintenance and monitoring of research models, and those which are designed to implement efficacy screening protocols to improve the client's drug evaluation process. The Company also offers four other categories of products and services within RMS - Genetically Engineered Models and Services, Insourcing Solutions, Discovery Research Services and Research Animal Diagnostic Services. The Company is a supplier of SPF fertile chicken eggs and chickens. SPF chicken embryos are used by animal health companies as self-contained "bioreactors" for the manufacture of live viruses. The EMD business provides non-animal, or in vitro, methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. In 2012, the EMD business acquired Accugenix, a provider of cGMP- compliant contract microbial identification testing. The Company is a provider of preclinical services both regulated and non-regulated, in which it includes both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development It currently provides preclinical services at multiple facilities located in the United States, Canada and Europe. It competes in the marketplace on the basis of its therapeutic and scientific expertise in in vivo biology, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. As the Company's business operates in a number of distinct operating environments and in a variety of locations worldwide, it is subject to numerous, and sometimes overlapping, regulatory environments.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide